CGNX vs CLBT: fair value comparison
Cognex Corporation and Cellebrite DI Ltd. · Updated 2026-10-19
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Technology, CLBT currently sits closer to the top of our ranking by discount to fair value.
| CGNX | CLBT | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $53.99 | $11.03 |
| 12-month range | $34.80–$72.42 | $10.44–$19.28 |
| Rank by discount to fair value | #31 of 181 Technology | #26 of 181 Technology |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Expanding | Contracting |
| Revenue growth | Strong | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Downtrend |
| DCF cross-check | — | Overvalued |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: CGNX fair value analysis · CLBT fair value analysis